Adenomatous polyposis Coli/β-catenin interaction and downstream targets: Altered gene expression in gastrointestinal tumors

Clinical Colorectal Cancer

Volumn 3, Issue 2, 2003, Pages 113-120

  Clements, Wilson M ^a   Lowy, Andrew M ^a   Groden, Joanna ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Colorectal cancer; Frizzled receptors; Gastric cancer; Signal transduction; Wnt signaling

Indexed keywords

APC PROTEIN; AXIN; BETA CATENIN; BINDING PROTEIN; CONNEXIN 43; CYCLIN D1; CYCLOOXYGENASE 2; GASTRIN; GLYCOGEN SYNTHASE KINASE 3; KALININ; LIGAND; LYMPHOID ENHANCER FACTOR 1; MATRILYSIN; MYC PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; SURVIVIN; TRANSCRIPTION FACTOR; WNT PROTEIN;

ADENOMATOUS POLYP; COLON CARCINOGENESIS; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; FAMILIAL CANCER; GASTROINTESTINAL TRACT; GASTROINTESTINAL TUMOR; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENETIC REGULATION; HUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR SUPPRESSOR GENE; UNITED STATES;

EID: 0041380990     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2003.n.018     Document Type: Article

References (93)

1. American Cancer Society. Cancer Facts & Figures 2002. Atlanta, GA: American Cancer Society, 2002.
2. Bodmer WF, Bailey CJ, Bodmer J, et al. Localization of the gene for familial adenomatous polyposis coli on chromosome 5. Nature 1987; 328:614-616.
3. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991; 66:589-600.
4. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971; 68:820-823.
5. Ransohoff DF, Lang CA. Screening for colorectal cancer. N Engl J Med 1991; 325:37-41.
6. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87:159-170.
7. Jen J, Powell SM, Papadopoulos N, et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 1994; 54:5523-5526.
8. Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Cell Dev Biol 1998; 14:59-88.
9. Moon RT, Brown JD, Torres M. WNTs modulate cell fate and behavior during vertebrate development. Trends Genet 1997; 13:157-162.
10. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14:1837-1851.
11. Liu C, Li Y, Semenov M, et al. Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108:837-847.
12. Hart M, Concordet JP, Lassot I, et al. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 1999; 9:207-210.
13. Bhanot P, Brink M, Samos CH, et al. A new member of the frizzled family from Drosophila functions as a wingless receptor. Nature 1996; 282:225-230.
14. Yang-Synder J, Miller JR, Huang E, et al. A frizzled homolog functions in a vertebrate Wnt signaling pathway. Curr Biol 1996; 6:1302-1306.
15. He X, Saint-Jeannet JP, Wang Y, et al. A member of the Frizzled protein family mediating axin induction by Wnt-5A. Science 1997; 275:1652-1654.
16. Liu T, DeCostanzo AJ, Liu X, et al. G protein signaling from activated rat Frizzled-1 to the β-catenin-Lef-Tcf pathway. Science 2001; 292:1718-1722.
17. Lee JS, Ishimoto A, Yanagawa S. Characterization of mouse disheveled (Dv1) proteins in Wnt/Wingless signaling pathway. J Biol Chem 1999; 274:21464-21470.
18. Orford K, Crockett C, Jensens JP, et al. Serine phosphorylation-regulated ubiquitination and degradation of β-catenin. J Biol Chem 1997; 272:24735-24738.
19. Behrens J, von Kries JP, Kuhl M, et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996; 382:638-642.
20. Molenaar M, van de Wetering M, Oosterwegel M, et al. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 1996; 86:391-399.
21. He TC, Sparks A, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281:1509-1512.
22. Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-426.
23. Crawford HC. Fingleton BM, Rudolph-Owen LA, et al. The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors. Oncogene 1999; 18:2883-2891.
24. He TC, Chan TA, Vogelstein B, et al. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99:335-345.
25. Koh TJ, Bulitta CJ, Fleming JV, et al. Gastrin is a target of the beta-catenin/TCF-4 growth- signaling pathway in a model of intestinal polyposis. J Clin Invest 2000; 106:533-539.
26. Ai Z, Fischer A, Spray DC, et al. Wnt-1 regulation of connexin 43 in cardiac myocytes. J Clin Invest 2000; 105:161-171.
27. Pennica D, Swanson TA, Welsh JW, et al. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A 1998; 95:14717-14722.
28. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982; 31: 99-109.
29. Katoh M. Expression and regulation of WNT1 in human cancer: Up-regulation of WNT1 by beta-estradiol in MCF-7 cells. Int J Oncol 2003; 22:209-212.
30. Katoh M, Kirikoshi H, Terasaki H, et al. WNT2B2 mRNA, up-regulated in primary gastric cancer, is a positive regulator of the WNT β-catenin-TCF signaling pathway. Biochem Biophys Res Commun 2001; 289:1093-1098.
31. Saitoh T, Kirikoshi H, Mine T, et al. Proto-oncogene WNT10B is up-regulated by tumor necrosis factor alpha in human gastric cancer cell line MKN45. Int J Oncol 2001; 6:1187-1192.
32. Saitoh T, Mine T, Katoh M. Frequent up-regulation of WNT5A mRNA in primary gastric cancer. Int J Mol Med 2002; 9:515-519.
33. Gazit A, Yaniv A, Bafico A, et al. Human frizzled 1 interacts with transforming Wnts to transduce a TCF dependent transcriptional response. Oncogene 1999; 18:5959-5966.
34. Leyns L, Bouwmeester T. Kim SH, et al. Frzβ1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer. Cell 1997; 88:747-756.
35. Wang S, Krinks M, Lin K, et al. Frzb, a secreted protein expressed in the Spemann organizer, binds and inhibits Wnt-8. Cell 1997; 88:757-766.
36. To KF, Chan MW, Leung WK, et al. Alterations of frizzled (FzE3) and secreted frizzled related proteins (hsFRP) in gastric cancer. Life Sci 2001; 70:483-489.
37. Tanaka S, Akiyoshi T, Mori M, et al. A novel frizzled gene identified in human esophageal carcinoma mediates APC/beta-catenin signals. Proc Natl Acad Sci U S A 1998; 95:10164-10169.
38. Kirikoshi H, Sekihara H, Katoh M. Up-regulation of Frizzled-7 (FZD7) in human gastric cancer. Int J Oncol 2001; 19:111-115.
39. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21:163-167.
40. Jonkers J, Weening JJ, van der Valk M, et al. Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression. Oncogene 1999; 18:5982-5990.
41. Saitoh T, Katoh M. FRAT1 and FRAT2, clustered in human chromosome 10q24.1 region, are up-regulated in gastric cancer. Int J Oncol 2001; 19:311-315.
42. Satoh S, Daigo Y, Furukawa Y. et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000; 24:245-250.
43. Lustig B, Jerchow B, Sachs M, et al. Negative feedback loop of Wnt signaling through upregulation of Conductin/Axin2 in colorectal and liver tumors. Mol Cell Biol 2002; 22:1184-1193.
44. Liu W, Dong X, Mai R, et al. Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet 2000; 26:146-147.
45. Rubinfeld B, Albert I, Porfiri E, et al. Binding of GSK3beta to the APC-beta catenin complex and regulation of complex assembly. Science 1996; 272:1023-1026.
46. Yamamoto H, Kishida S, Kishida M, et al. Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability. J Biol Chem 1999; 274:10681-10684.
47. Kishida S, Yamamoto H, Ikeda S, et al. Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin. J Biol Chem 1998; 273:10823-10826.
48. Hedgepeth CM, Deardorff MA, Rankin K, et al. Regulation of glycogen synthase kinase 3beta and downstream Wnt signaling by axin. Mol Cell Biol 1999: 19:7147-7157.
49. Nakamura T, Hamada F, Ishidate T, et al. Axin, an inhibitor of the Wnt signaling pathway, interacts with beta-catenin, GSK-3beta and APC and reduces the beta-catenin level. Genes Cells 1998; 3:395-403.
50. Sparks AB, Morin PJ, Vogelstein B, et al. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998; 58:1130-1134.
51. Li L, Yuan H, Weaver CD, et al. Axin and Frat1 interact with dv1 and GSK, bridging Dv1 to GSK in Wnt-mediated regulation of LEF-1. EMBO J 1999; 18:4233-4240.
52. Ferkey DM, Kimelman D. Glycogen synthase kinase-3 beta mutagenesis identifies a common binding domain for GBP and Axin. J Biol Chem 2002; 277:16147-16152.
53. Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 2000; 18: 1967-1979.
54. Su LK, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein with catenins. Science 1993; 262:1734-1737.
55. Rubinfeld B, Albert I, Porfiri E, et al. Association of the APC gene product with β-catenin. Science 1993; 262:1731-1734.
56. Munemitsu S, Albert I, Souza B, et al. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor suppressor protein. Proc Natl Acad Sci U S A 1995; 92:3046-3050.
57. Kielman MF, Rindapaa M, Gaspar C, et al. Ape modulates embryonic stem-cell differentiation by controlling the dosage of beta-catenin signaling. Nat Genet 2002; 32:594-605.
58. Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-Tcf signaling in colon caner by mutations in β-catenin or APC. Science 1997; 275:1787-1790.
59. Shih IM, Yu J, He TC, et al. The β-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. Cancer Res 2000; 60:1671-1676.
60. Roh H, Green DW, Boswell CB, et al. Suppression of β-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells. Cancer Res 2001; 61:6563-6568.
61. Rosin-Arbesfeld R, Townsley F, Bienz M. The APC tumor suppressor has a nuclear export function. Nature 2000; 406:1009-1012.
62. Henderson BR. Nuclear-cytoplasmic shuttling of APC regulates β-catenin subcellular localization and turnover. Nat Cell Biol 2000; 2:653-660.
63. Neufeld KL, Zhang F, Cullen BR, et al. APC-mediated downregulation of β-catenin activity involves nuclear sequestration and nuclear export. EMBO Rep 2000; 1:519-523.
64. Henderson BR, Fagotto F. The ins and outs of APC and beta-catenin nuclear transport. EMBO Rep 2002; 3:834-839.
65. Esteller M, Sparks A, Toyota M, et al. Analysis of Adenomatous Polyposis Coli promoter hypermethylation in human cancer. Cancer Res 2000; 60:4366-4371.
66. Behrens J, Jerchow BA, Wurtele J, et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 1998; 280:596-599.
67. Zeng L, Fagotto F, Zhang W, et al. The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell 1997; 90:181-192.
68. Yamamoto H, Kishida T, Unochi S, et al. Axil, a member of the Axin family, interacts with both glycogen synthase kinase 3β and β-catenin and inhibits axis formation in Xenopus embryos. Mol Cell Biol 1998; 18:2867-2875.
69. Jho EH, Zhang T, Domon C, et al. Wnt/β-catenin signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 2002; 22:1172-1183.
70. Mirabelli-Primdahl L, Gryfe R, Kim H, et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 1999; 59:3346-3351.
71. Miyaki M, Iijima T, Kimura J, et al. Frequent mutation of beta-catenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer. Cancer Res 1999; 59:4506-4509.
72. Kolligs FT, Nieman MT, Winer I, et al. ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with β-catenin defects and promotes neoplastic transformation. Cancer Cell 2002; 1:145-155.
73. Su F, Overholtzer M, Besser D, et al. WISP-1 attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase. Genes Dev 2002; 16:46-57.
74. Howe LR, Crawford HC, Subbaramaiah K, et al. PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenase-2. J Biol Chem 2001; 276:20108-20115.
75. Zhang T, Otevral T, Gao Z, et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2001; 61:8664-8667.
76. Fujita M, Furukawa Y, Tsunoda T, et al. Up-regulation of the ectodermal-neural cortex 1 (ENC1) gene, a downstream target of the β-catenin/T-cell factor complex, in colorectal carcinoma. Cancer Res 2001; 61:7722-7726.
77. Hlubek F, Jung A, Kotzor N, et al. Expression of the invasion factor laminin γ2 in colorectal carcinoma is regulated by β-catenin. Cancer Res 2001; 61:8089-8093.
78. Xu L, Corcoran RB, Welsh JW, et al. WISP-1 is a Wnt-1 and β-catenin-responsive oncogene. Genes Dev 2000; 14:585-595.
79. Tanaka S, Sugimachi K, Saeki H, et al. A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma. Oncogene 2001; 20:5525-5532.
80. Thorstensen L, Diep CB, Meling CI, et al. WNT1 inducible signaling pathway protein 3, WISP-3, a novel target gene in colorectal carcinomas with microsatellite instability. Gastroenterology 2001; 121:1275-1280.
81. Fingleton BM, Heppner Goss KJ, Crawford HC, et al. Matrilysin in early stage intestinal tumorigenesis. APMIS 1999; 107:102-110.
82. Crawford HC, Fingleton B, Gustavson MD, et al. The PEA3 subfamily of Ets transcription factors synergizes with β-catenin-Lef-1 to activate matrilysin transcription in intestinal tumors. Mol Cell Biol 2001; 21:1370-1383.
83. Takahashi M, Tsunoda T, Seiki M, et al. Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers. Oncogene 2002; 21:5861-5867.
84. Kawasaki H. Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58:5071-5074.
85. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87:803-809.
86. Oshima M, Murai N, Kargman S, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61:1733-1740.
87. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342:1946-19452.
88. Nugent KP, Farmer KC, Spigelman AD, et al. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993; 80:1618-1619.
89. Watson SA, Gilliam AD. G17DT - a new weapon in the therapeutic armoury for gastrointestinal malignancy. Expert Opin Biol Ther 2001; 1:309-317.
90. Yamamoto T, Manome Y, Nakamura M, et al. Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer 2002; 38:2316-2324.
91. Adachi Y, Itoh F, Yamamoto H, et al. Retinoic acids reduce matrilysin (matrix metalloproteinase 7) and inhibit tumor cell invasion in human colon cancer. Tumour Biol 2001; 22:247-253.
92. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119:1219-1227.
93. Arango D, Corner GA, Wadler S, et al. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res 2001: 61:4910-4915.